{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Any adverse event that ws at least possibly related to study treatment and met protocol-specified criteria was classified as a DLT. For the purpose of dose finding, decisions on dose were based on DLTs observed during the first 21 days of treatment.","groups":[{"description":"Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.","id":"OG000","title":"INCB099280 400 mg BID Plus Axitinib 5 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT-Evaluable Population: all participants in Part 1 who had a DLT during the 3-week DLT observation period or received at least 75% of the planned doses of both INCB099280 and axitinib at the assigned dose.","reportingStatus":"POSTED","timeFrame":"up to 3 weeks","title":"Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}